Cangrelor in addition to standard therapy reduces cardiac damage and inflammatory markers in patients with ST-segment elevation myocardial infarction

Mohamed Abo‐Aly(University of Kentucky), Khaled M. Ziada(Cleveland Clinic), Elica Shokri(University of Kentucky), Bennet George(University of Kentucky), Ahmed Abdel‐Latif(University of Kentucky), Lakshman Chelvarajan(University of Kentucky), Susan S. Smyth(University of Kentucky), Mohamed El-Helw(University of Kentucky)
Journal of Thrombosis and Thrombolysis
November 30, 2020
10.1007/s11239-020-02345-8
Cited by 11

Related Papers

Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial
|The Lancet|2018|781
Extent and Direction of Arterial Remodeling in Stable Versus Unstable Coronary Syndromes
|Circulation|2000|751
High Prevalence of Coronary Atherosclerosis in Asymptomatic Teenagers and Young Adults
|Circulation|2001|681
Safety and tolerability of SCH 530348 in patients undergoing non-urgent percutaneous coronary intervention: a randomised, double-blind, placebo-controlled phase II study
|The Lancet|2009|298
Arterial remodeling and coronary artery disease: the concept of “dilated” versus “obstructive” coronary atherosclerosis
|Journal of the American College of Cardiology|2001|290